EMERYVILLE, Calif.,
Sept. 7, 2021 /PRNewswire/ -- Amyris,
Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company in
Clean Health and Beauty markets through its consumer brands and a
top supplier of sustainable and natural ingredients, today
announced that, on August 31, it
closed the acquisition of Beauty Labs International Ltd. ("Beauty
Labs"), a leader in AI technology that provides breakthrough
connected consumer experiences to the beauty and wellness
community.
Amyris is accelerating its growth and market leadership in clean
beauty by adding digital innovation, machine learning and data
science to further enhance the consumer experience of its family of
consumer brands consisting of Biossanceâ, Pipetteâ, Terasanaâ,
Costa Brazil, OLIKA, Rose Inc. ™and JVN™, These Amyris brands
will leverage Beauty Labs' leading AI technology to create
compelling, personalized, connected consumer experiences and
further accelerate the growth of Amyris' ecommerce revenue.
Beauty Labs is a data sciences and machine learning
technology company that has developed one of the leading consumer
applications for "try before you buy" color cosmetics. This
technology applies the power of machine learning and AI technology
to match color cosmetics products with skin tone. Beauty Labs is
also developing advanced software that assesses skin conditions to
make product recommendations to improve skin health, along with a
user interface to track acne and other skin conditions so that
consumers can fully benefit from the suite of Amyris' leading clean
beauty and skin treatment offerings.
Amyris has already commenced the integration of the Beauty Labs
technology into its direct-to-consumer websites with promising
early results on the Rose Inc. direct-to-consumer channel of a
higher conversion to purchase for consumers using the color
matching technology. Beauty Labs and MG Empower, the influencer
marketing and digital innovation partner acquired by Amyris last
month, represent critical components of Amyris' strategy of
deepening the beauty consumer relationship and delivering the best
digital retail beauty experience. These technologies deepen the
consumer experience of Amyris' unique portfolio connection from the
creation of differentiated sustainable ingredients by its
Lab-to-Market™ science and technology to the
formulation into consumer products that are better for people and
the planet. Amyris' path to manufacturing at scale and to
commercializing ingredients outpaces its peer group in synthetic
biology. Squalane, Hemisqualane, Biosilica and CBG, Amyris
ingredients that are naturally produced from clean fermentation,
differentiate consumer-oriented products and deliver significant
revenue growth. The bridge between ingredients, clean beauty
products and ecommerce technologies evidence the power of Amyris'
vertically integrated business model and its deep connection with
the consumer.
"We are delivering the fastest revenue growth of any synthetic
biology platform in the world and generate more total revenue than
the aggregate of our immediate peers," commented John Melo, President and Chief Executive Officer
of Amyris. "We are advancing our leadership position by deepening
the relationship with consumers to enable us to deliver more value
while increasing our share of wallet through our direct-to-consumer
business. Influencers are increasingly becoming the direct sellers
of product through their platforms and we want to lead this
transition with data science. We are already benefiting from these
strategic moves and are on track to deliver our best quarter in
consumer revenue by far."
About Beauty Labs
Beauty Labs International Ltd.,
wholly owned by Amyris, with bases in both the UK and US, is a
technology company that pioneers the future of enhanced reality in
beauty and wellness. Consumer expectations are rapidly changing,
and they are looking for brands and products that understand 'who'
they are and 'what' they stand for in a personalized and
interactive way. Beauty Labs enhanced reality experiences put the
customer first, embracing their sense of immediacy, leveraging the
familiar, and keeping interactive moments short and assistive.
About Amyris
Amyris (Nasdaq: AMRS) is a science and
technology leader in the research, development and production of
sustainable ingredients for the Clean Health & Beauty and
Flavors & Fragrances markets. Amyris uses an impressive array
of exclusive technologies, including state-of-the-art machine
learning, robotics and artificial intelligence. Our ingredients are
included in over 20,000 products from the world's top brands,
reaching more than 300 million consumers. Amyris is proud to own
and operate a family of consumer brands - all built around its No
Compromise® promise of clean ingredients: Biossanceâ clean
beauty skincare, Pipetteâ clean baby skincare, Purecane™, a
zero-calorie sweetener naturally derived from sugarcane,
Terasanaâ clean skincare treatment, Costa Brazil luxury
skincare, OLIKA hygiene and wellness, Rose Inc.™ clean color
cosmetics and JVN™ clean haircare. For more information, please
visit http://www.amyris.com.
Amyris, the Amyris logo, No Compromise, Biossance, Pipette,
Purecane, Terasana, Rose Inc. and Lab-to-Market are trademarks or
registered trademarks of Amyris, Inc. in the U.S. and/or other
countries.
Forward-Looking Statements
This release contains
forward-looking statements, and any statements other than
statements of historical fact could be deemed to be forward-looking
statements. These forward-looking statements include, among
other things, statements regarding Amyris' expectations that the
Beauty Labs acquisition will contribute to Amyris' growth and
market leadership by enhancing the consumer experience of its
family of brands; Amyris' belief that its manufacturing and
commercialization capability outpaces its synthetic biology peer
group and that it is delivering the fastest revenue growth
of any synthetic biology platform in the world and generating more
total revenue than the aggregate of its immediate peers; and
Amyris' expectations regarding delivering its best quarter in
consumer revenue. These statements are based on management's
current expectations and actual results and future events may
differ materially due to risks and uncertainties, including risks
related to any delays or failures in the successful launch of a
clean skincare brand; potential delays or failures in development,
production, regulatory approval and commercialization of products,
risks related to Amyris' reliance on third parties; Amyris'
liquidity and ability to fund operating and capital expenses; and
other risks detailed from time to time in filings Amyris makes with
the Securities and Exchange Commission, including Annual Reports on
Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on
Form 8-K. Amyris disclaims any obligation to update information
contained in these forward-looking statements, whether as a result
of new information, future events, or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/amyris-closes-acquisition-of-beauty-labs-combining-synthetic-biology-leadership-with-digital-innovation-301370025.html
SOURCE Amyris, Inc.